A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

Oncotarget

Volumn 8, Issue 13, 2017, Pages 22104-22112

  Jain, Nitin ^a   Balakrishnan, Kumudha ^a   Ferrajoli, Alessandra ^a   O'Brien, Susan M ^b   Burger, Jan A ^a   Kadia, Tapan M ^a   Cortes, Jorge E ^a   Ayres, Mary L ^a   Tambaro, Francesco Paolo ^c   Keating, Michael J ^a   Gandhi, Varsha ^a   Wierda, William G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

Author keywords

Bendamustine; Chemoimmunotherapy; CLL; Fludarabine; Rituximab

Indexed keywords

ACICLOVIR; ATM PROTEIN; BENDAMUSTINE; CHECKPOINT KINASE 2; COTRIMOXAZOLE; FLUDARABINE; HISTONE H2AX; PROTEIN BAX; PROTEIN MCL 1; PROTEIN P53; RITUXIMAB; VALACICLOVIR; ANTINEOPLASTIC AGENT; VIDARABINE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; DEHYDRATION; DNA DAMAGE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HERPES VIRUS INFECTION; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MEDIAN SURVIVAL TIME; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CANCER STAGING; CLINICAL TRIAL; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RITUXIMAB; SURVIVAL RATE; VIDARABINE;

EID: 85016426772     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12054     Document Type: Article

References (24)

1. Jain N and O'Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015; 126:463-470.
2. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A and Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of clinical oncology. 2005; 23:4079-4088.
3. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S and Keating MJ. Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112:975-980.
4. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376:1164-1174.
5. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H and Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011; 117:3016-3024.
6. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of clinical oncology. 2010; 28:1756-1765.
7. Gandhi V and Burger JA. Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res. 2009; 15:7456-7461.
8. Hartmann M and Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta. 1972; 287:386-389.
9. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G and Niemeyer CC. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14:309-317.
10. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Bottcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Buhler A, Winkler D, Kneba M, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of clinical oncology. 2011; 29:3559-3566.
11. Yamauchi T, Nowak BJ, Keating MJ and Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001; 7:3580-3589.
12. Rao VA and Plunkett W. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine. Clin Cancer Res. 2003; 9:3204-3212.
13. Sandoval A, Consoli U and Plunkett W. Fludarabinemediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res. 1996; 2:1731-1741.
14. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S and Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of clinical oncology. 2001; 19:1414-1420.
15. El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG and Gandhi V. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood. 2014; 123:3780-3789.
16. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol. 2002; 29:4-11.
17. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H and Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of clinical oncology. 2005; 23:4070-4078.
18. Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA and Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, welltolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of clinical oncology. 2006; 24:1575-1581.
19. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H and Wierda WG. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011; 118:2085-2093.
20. Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC and investigators Lt. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. British journal of haematology. 2014; 167:466-477.
21. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Jr. and Gulbis A. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014; 124:2306-2312.
22. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ and International Workshop on Chronic Lymphocytic L. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111:5446-5456.
23. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL and Gandhi V. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015; 29:1811-1822.
24. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG and Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010; 116:1083-1091.